Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Enovis (ENOV) Shares Repurchased (2015 - 2019)

Enovis (ENOV) reported Shares Repurchased of -$377.8 million for Q2 2019, down 362.55% year-over-year from $143.9 million in Q2 2018, and down 200.0% on a QoQ basis from $377.8 million in Q1 2019.

Enovis (ENOV) has 4 years of Shares Repurchased data on file, last reported at -$377.8 million in Q2 2019.

  • Quarterly Shares Repurchased fell 362.55% year-over-year to -$377.8 million in Q2 2019, while the trailing twelve-month figure through Jun 2019 was $56.1 million (down 61.02% YoY) and the FY2025 annual result came in at $3.5 million, down 26.57% from the prior year.
  • Shares Repurchased eased to -$377.8 million in Q2 2019 per ENOV's latest filing, from $377.8 million in the prior quarter.
  • Across five years, Shares Repurchased topped out at $377.8 million in Q1 2019 and bottomed at -$377.8 million in Q2 2019.
  • The 4-year median for Shares Repurchased is $41.7 million (2015), against an average of $41.4 million.
  • Peak annual rise in Shares Repurchased reached 362.55% in 2019, while the deepest fall reached 362.55% in 2019.
  • Tracing ENOV's Shares Repurchased over 4 years: stood at $27.4 million in 2015, then declined by 23.95% to $20.8 million in 2016, then soared by 169.55% to $56.1 million in 2018, then slumped by 773.49% to -$377.8 million in 2019.
  • Per Business Quant, the three latest ENOV Shares Repurchased figures stand at -$377.8 million (Q2 2019), $377.8 million (Q1 2019), and $56.1 million (Q3 2018).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares Repurchased (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 180.00 Mn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 105.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 421.80 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 100.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 74.30 Mn
10 Enovis 1.25 Bn 1.22 Bn 365.49 Mn -

Historic Data

Download Data 🔒
DateValue
Jun 28, 2019 -377.81 Mn
Jun 28, 2019 -377.81 Mn
Mar 29, 2019 377.81 Mn
Mar 29, 2019 377.81 Mn
Sep 28, 2018 56.10 Mn
Sep 28, 2018 56.10 Mn
Jun 29, 2018 143.90 Mn
Jun 29, 2018 143.90 Mn
Apr 1, 2016 20.81 Mn
Apr 1, 2016 20.81 Mn
Dec 31, 2015 27.37 Mn
Dec 31, 2015 27.37 Mn